SPRED1 deletion confers resistance to MAPK inhibition in melanoma

被引:19
|
作者
Ablain, Julien [1 ,2 ]
Liu, Sixue [3 ,5 ]
Moriceau, Gatien [3 ,5 ,6 ]
Lo, Roger S. [3 ,4 ,5 ,6 ]
Zon, Leonard, I [1 ,2 ,7 ,8 ]
机构
[1] Boston Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Calif Los Angeles, Dept Med, Div Dermatol, Los Angeles, CA 90024 USA
[4] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[6] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[7] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA
[8] Howard Hughes Med Inst, Boston, MA 02115 USA
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 2021年 / 218卷 / 03期
基金
美国国家卫生研究院;
关键词
LEGIUS SYNDROME; PROTEIN; BRAF; DOMAIN; NF1; VEMURAFENIB; EFFICACY; MUTANTS; ENCODES; PATHWAY;
D O I
10.1084/jem.20201097
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Functional evaluation of genetic lesions can discover a role in cancer initiation and progression and help develop novel therapeutic strategies. We previously identified the negative MAPK regulator SPRED1 as a novel tumor suppressor in KIT-driven melanoma. Here, we show that SPRED1 is also frequently deleted in human melanoma driven by mutant BRAF. We found that SPRED1 inactivation in human melanoma cell lines and primary zebrafish melanoma conferred resistance to BRAF(V600E) inhibition in vitro and in vivo. Mechanistically, SPRED1 loss promoted melanoma cell proliferation under mutant BRAF inhibition by reactivating MAPK activity. Consistently, biallelic deletion of SPRED1 was observed in a patient whose melanoma acquired resistance to MAPK-targeted therapy. These studies combining work in human cells and in vivo modeling in zebrafish demonstrate a new mechanism of resistance to BRAF(V600E) inhibition in melanoma.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] SPRED1 IS A TUMOR SUPPRESSOR IN MUCOSAL MELANOMA
    不详
    CANCER DISCOVERY, 2018, 8 (12) : 1507 - 1507
  • [2] The role of Spred1 and the Ras/MAPK pathway in sepsis
    Morgner, S.
    Naeem, Z.
    Krueger, T.
    Kniemeyer, O.
    Biskup, C.
    Rubio, I
    INFECTION, 2019, 47 : S15 - S15
  • [3] Mosaicism for a SPRED1 deletion revealed in a patient with clinically suspected mosaic neurofibromatosis
    Jobling, R. K.
    Lara-Corrales, I.
    Hsiao, M. -C.
    Shugar, A.
    Hedges, S.
    Messiaen, L.
    Kannu, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (04) : 1077 - 1078
  • [4] SPRED1 Mutations in a Neurofibromatosis Clinic
    Muram-Zborovski, Talia M.
    Stevenson, David A.
    Viskochil, David H.
    Dries, David C.
    Wilson, Andrew R.
    Mao, Rong
    JOURNAL OF CHILD NEUROLOGY, 2010, 25 (10) : 1203 - 1209
  • [5] Spred1 deficit promotes treatment resistance and transformation of chronic phase CML
    Qiao, Junjing
    Liang, Chen
    Zhao, Dandan
    Le Xuan Truong Nguyen
    Chen, Fang
    Suo, Shanshan
    Dinh Hoa Hoang
    Pellicano, Francesca
    Rodriguez, Ivan Rodriguez
    Elhajmoussa, Yasmin
    Ghoda, Lucy
    Yoshimura, Akihiko
    Stein, Anthony S.
    Ali, Haris
    Koller, Paul
    Perrotti, Danilo
    Copland, Mhairi
    Han, Anjia
    Zhang, Bin Amber
    Marcucci, Guido
    LEUKEMIA, 2022, 36 (02) : 492 - 506
  • [6] The SPRED1 Variants Repository for Legius Syndrome
    Sumner, Kelli
    Crockett, David K.
    Muram, Talia
    Mallempati, Kalyan
    Best, Hunter
    Mao, Rong
    G3-GENES GENOMES GENETICS, 2011, 1 (06): : 451 - 455
  • [7] SPRED1 disorder and predisposition to leukemia in children
    Pasmant, Eric
    Ballerini, Paola
    Lapillonne, Helene
    Perot, Christine
    Vidaud, Dominique
    Leverger, Guy
    Landman-Parker, Judith
    BLOOD, 2009, 114 (05) : 1131 - 1131
  • [8] Role of SPRED1 in keratinocyte proliferation in psoriasis
    Li, Xinhua
    Li, Junqin
    Lu, Funa
    Cao, Yue
    Xing, Jianxiao
    Li, Juan
    Hou, Ruixia
    Yin, Guohua
    Zhang, Kaiming
    JOURNAL OF DERMATOLOGY, 2020, 47 (07): : 735 - 742
  • [9] Spred1 deficit promotes treatment resistance and transformation of chronic phase CML
    Junjing Qiao
    Chen Liang
    Dandan Zhao
    Le Xuan Truong Nguyen
    Fang Chen
    Shanshan Suo
    Dinh Hoa Hoang
    Francesca Pellicano
    Ivan Rodriguez Rodriguez
    Yasmin Elhajmoussa
    Lucy Ghoda
    Akihiko Yoshimura
    Anthony S. Stein
    Haris Ali
    Paul Koller
    Danilo Perrotti
    Mhairi Copland
    Anjia Han
    Bin (Amber) Zhang
    Guido Marcucci
    Leukemia, 2022, 36 : 492 - 506
  • [10] Oncogenic RTK signaling inhibits Spred1/NF1 to sustain constitutive Ras/MAPK signaling
    Markegard, Evan
    Mercado, Ellen L.
    Castel, Pau
    Silva, Jillian
    Galeas, Jacqueline
    Li, Kathy
    Urisman, Anatoly
    McCormick, Frank
    CANCER RESEARCH, 2018, 78 (13)